Eli Lilly & Co. (NYSE: LLY) has signed a licensing agreement with OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a South Korea-based RNAi therapeutics developer, to jointly develop and commercialize OLX75016, an investigational drug targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications.
Drug Profile
OLX75016, derived from a genome-wide association study (GWAS), is a Phase 1 candidate designed to treat MASH and related cardiovascular metabolic diseases. Preclinical studies have demonstrated efficacy in addressing MASH, liver fibrosis, and other metabolic conditions.
Agreement Details
Under the deal, OliX will receive an undisclosed upfront payment from Lilly to complete an ongoing Phase I study of OLX75016 in Australia. The collaboration aims to advance the drug’s development for global markets.
Strategic Outlook
The partnership leverages OliX’s RNAi expertise and Lilly’s global R&D capabilities. OLX75016’s potential to address unmet needs in cardiometabolic diseases positions it as a key asset in Lilly’s pipeline.-Fineline Info & Tech
